Cryopreservation of Ovarian Cortex in Girls With Turner Syndrome (CRYO-X0)
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Ovarian insufficiency is common in Turner syndrome related to premature and rapid follicular apoptosis and spontaneous pregnancies are rare in this population. Ovarian cryopreservation has been used in an effort to preserve fertility in patients undergoing treatments which lead to premature and severe ovarian insufficiency. This study aims to assess the relevance of ovarian tissue cryopreservation in girls with Turner syndrome. Based on ovarian follicular density as primary outcome and karyotypic, clinical and hormonal markers as secondary outcomes, analysis of the study will allow to select the patients to whom the procedure would benefit the most.
| Condition | Intervention |
|---|---|
|
Turner Syndrome Ovarian Insufficiency |
Procedure: Ovariectomy |
| Study Type: | Interventional |
| Study Design: | Endpoint Classification: Efficacy Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Prevention |
| Official Title: | Cryopreservation of Ovarian Cortex in Girls With Turner Syndrome : Karyotypic, Clinical and Hormonal Criteria to Screen Patients |
- the ovarian follicular density [ Time Frame: at the time of the ovariectomy ] [ Designated as safety issue: No ]the specific measure is the ovarian follicular density which will allow to Identify criteria, to predict existence or absence of ovarian follicles at the time of the surgery
- measure hormonal markers [ Time Frame: Before the ovariectomy, 1 month and 12 months after the ovariectomy ] [ Designated as safety issue: No ]measure hormonal markers as FSH, AMH, Inhibine B and estradiol before, at one month and one year after the ovariectomy
| Estimated Enrollment: | 40 |
| Study Start Date: | January 2011 |
| Estimated Study Completion Date: | April 2014 |
| Estimated Primary Completion Date: | January 2014 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: Surgery
Ovariectomy
|
Procedure: Ovariectomy
Ovarian cryopreservation has been used in an effort to preserve fertility in patients undergoing treatments which lead to premature and severe ovarian insufficiency.
Other Name: Ovariectomy
|
Detailed Description:
Turner syndrome (TS) is characterized by the absence of all or part of a normal second X chromosome and occurs in about 1/2,500 live-born girls. Spontaneous fertility is rare among patients with TS related to premature apoptosis of ovarian follicles. Spontaneous puberty and fertility has been reported mostly in patients with mosaic karyotype or small X deletions.
There is robust evidence that follicles can be observed in ovaries in girls with TS. However, follicular density and quality seems to be largely influenced by karyotype, ovarian morphology and endocrine competence. There are no clear-cut clinical or hormonal markers to assess the ovarian reserve in girls with TS but markers of ovarian function used in women with premature ovarian insufficiency are measured. In TS, it is now fundamental to be able to evaluate the prognosis of the ovarian function and the degree of fertility to provide the relevant information to girls and their parents and to discuss possibilities of motherhood if any.
Ovarian cryopreservation has been used in an effort to preserve fertility in patients undergoing treatments which lead to premature and severe ovarian insufficiency. This study aims to assess the relevance of ovarian tissue cryopreservation in girls with Turner syndrome. Based on ovarian follicular density as primary outcome and karyotypic, clinical and hormonal markers as secondary outcomes, analysis of the study will allow to screen the patients to whom the procedure would benefit the most.
Girls who will be operated will accept to come for a follow-up visit at one and 12 months after the surgery. It is expected to have clinical and hormonal information through a long follow up performed by the referred paediatrician.
Results of the study will allow us to select patients with TS who will benefit the most of this fertility preservation procedure based on karyotypic, clinical and hormonal profile.
Eligibility| Ages Eligible for Study: | 1 Year to 25 Years |
| Genders Eligible for Study: | Female |
| Accepts Healthy Volunteers: | No |
Inclusion criteria :
- girls aged from 1 to 25 years included,
- with Turner syndrome or mosaic
- patients aged more than 18 will only have ovarian insufficiency dated less than 5 years
- without any severe disease, particularly of cardiovascular type
- whose agreement to participate to the study has been signed by the parents
- whose agreement to participate to the study has been signed by majority age patient
Exclusion criteria :
- girls aged less than one year and over 25 years old
- if any surgery would be contra-indicated
- ovary alone presence
- Well-known infection by HIV, and/or HBV, and/or HCV and/or syphilis TPHA VDRL
- No social coverage affiliate
Contacts and Locations| Contact: Lise Duranteau, MD, PhD | 0033145217842 | lise.duranteau@bct.aphp.fr |
| Contact: Laurence Lecomte, PhD | +33 1 71 19 64 94 | laurence.lecomte@nck.aphp.fr |
| France | |
| Hopital Bicetre | Recruiting |
| Kremlin-Bicetre, France, 94275 | |
| Principal Investigator: Lise Duranteau, MD, PhD | |
| Principal Investigator: | Lise Duranteau, MD, PhD | AP-HP |
More Information
No publications provided
| Responsible Party: | Assistance Publique - Hôpitaux de Paris |
| ClinicalTrials.gov Identifier: | NCT01410045 History of Changes |
| Other Study ID Numbers: | P081204 |
| Study First Received: | June 28, 2011 |
| Last Updated: | July 25, 2012 |
| Health Authority: | France: Ministry of Health |
Keywords provided by Assistance Publique - Hôpitaux de Paris:
|
Turner syndrome infertility ovarian insufficiency ovarian cryopreservation |
Additional relevant MeSH terms:
|
Primary Ovarian Insufficiency Turner Syndrome Gonadal Dysgenesis Menopause, Premature Ovarian Diseases Adnexal Diseases Genital Diseases, Female Gonadal Disorders Endocrine System Diseases Disorders of Sex Development |
Urogenital Abnormalities Sex Chromosome Disorders of Sex Development Heart Defects, Congenital Cardiovascular Abnormalities Cardiovascular Diseases Heart Diseases Congenital Abnormalities Sex Chromosome Disorders Chromosome Disorders Genetic Diseases, Inborn |
ClinicalTrials.gov processed this record on May 23, 2013